{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:41:48Z","timestamp":1760186508158,"version":"build-2065373602"},"reference-count":134,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.hoc.2014.06.008","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T02:31:51Z","timestamp":1406082711000},"page":"861-890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relapsed and Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"28","author":[{"given":"Silvia","family":"Gentili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.06.008_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.06.008_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.06.008_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2012.226","article-title":"Minor clone provides a reservoir for relapse in multiple myeloma","volume":"27","author":"Magrangeas","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib8","first-page":"258","article-title":"Association of response endpoints with survival outcomes in multiple myeloma","volume":"28","author":"Lonial","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.06.008_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","article-title":"Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma","volume":"19","author":"Palumbo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2014.06.008_bib11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-011-1217-0","article-title":"Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation\/maintenance therapy in patients with relapsed-refractory multiple myeloma","volume":"90","author":"Offidani","year":"2011","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.008_bib12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2009.015917","article-title":"The quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma","volume":"95","author":"Harousseau","year":"2010","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.hoc.2014.06.008_bib13","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.06.008_bib14","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.008_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2010.05.002","article-title":"Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains","volume":"35","author":"Chang","year":"2011","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2009.07728.x","article-title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma","volume":"146","author":"Chen","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/leu.2009.273","article-title":"Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone","volume":"24","author":"Avet-Loiseau","year":"2010","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.hoc.2014.06.008_bib19","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.008_bib21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.008_bib22","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/leu.2013.152","article-title":"Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study","volume":"27","author":"Jakubowiak","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib23","first-page":"408","article-title":"Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide\u00a0+ low-dose dexamethasone (POM\u00a0+ LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed\/refractory multiple myeloma (RRMM)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.008_bib24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.008_bib25","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-011-1206-3","article-title":"Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma","volume":"90","author":"Krejci","year":"2011","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib26","first-page":"686","article-title":"Patient outcomes by prior therapies and depth of response: analysis of MM-003, a phase 3 study comparing pomalidomide\u00a0+ low-dose dexamethasone (POM\u00a0+ LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed\/refractory multiple myeloma (RRMM)","volume":"122","author":"San Miguel","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bmt.2012.183","article-title":"Second auto-SCT for treatment of relapsed multiple myeloma","volume":"48","author":"Gonsalves","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.2009.07875.x","article-title":"Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"147","author":"Vogl","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.008_bib30","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cncr.23326","article-title":"Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide\/lenalidomide therapy","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.008_bib31","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.06.008_bib32","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","article-title":"Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment","volume":"90","author":"Klein","year":"2011","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib35","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","article-title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"51","author":"Chang","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.hoc.2014.06.008_bib36","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2014.06.008_bib37","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single- agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2014.06.008_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000322866","article-title":"Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicenter survey in Germany and Switzerland","volume":"79","author":"Hrusovsky","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.hoc.2014.06.008_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A\u00a0prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A\u00a0systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.008_bib42","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01121.x","article-title":"A\u00a0systematic review of phase II trials of thalidomide\/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma","volume":"81","author":"von Lilienfeld-Toal","year":"2008","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib44","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garcia-Sanz","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (hyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol J"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib48","first-page":"862","article-title":"Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma","volume":"91","author":"Sidra","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-004-0981-5","article-title":"Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study","volume":"84","author":"Hovenga","year":"2005","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.008_bib50","first-page":"1432","article-title":"Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study","volume":"88","author":"Offidani","year":"2003","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib51","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.2005.00610.x","article-title":"Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma","volume":"76","author":"Palumbo","year":"2006","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/MO:19:4:219","article-title":"Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma","volume":"19","author":"Srkalovic","year":"2002","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.008_bib53","first-page":"133","article-title":"Low dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.008_bib54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2008.07076.x","article-title":"Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial","volume":"143","author":"P\u00f6nisch","year":"2008","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.hoc.2014.06.008_bib56","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.hoc.2014.06.008_bib58","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.008_bib59","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07409.x","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program","volume":"144","author":"Mikhael","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.06.008_bib62","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","article-title":"Bortezomib in combination with dexamethasone for relapsed multiple myeloma","volume":"29","author":"Kropff","year":"2005","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.008_bib63","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2014.06.008_bib64","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib65","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and\u00a0melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib66","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2141.2008.07572.x","article-title":"Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma","volume":"144","author":"Popat","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"issue":"29","key":"10.1016\/j.hoc.2014.06.008_bib68","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.06.008_bib69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","article-title":"Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma","volume":"123","author":"Ludwig","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"Offidani","year":"2013","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.hoc.2014.06.008_bib71","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"124","author":"Richardson","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2014.06.008_bib72","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib73","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a\u00a0randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2014.06.008_bib74","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2014.06.008_bib75","first-page":"8514","article-title":"Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed\/refractory multiple myeloma (MM): results from a phase I study after full enrollment","volume":"31","author":"Kumar","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.008_bib76","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.008_bib77","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A\u00a0randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.008_bib78","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib79","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib80","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib81","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.008_bib82","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib83","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2141.2009.07931.x","article-title":"Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide\/dexamethasone-refractory myeloma","volume":"148","author":"van de Donk","year":"2010","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib84","first-page":"3055","article-title":"Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma","volume":"116","author":"Reece","year":"2010","journal-title":"ASH Annual Meeting Abstract"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib85","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib86","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study","volume":"150","author":"Schey","year":"2010","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.hoc.2014.06.008_bib87","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.008_bib88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.12361","article-title":"Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077","volume":"162","author":"P\u00f6nisch","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.008_bib89","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.008_bib90","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2014.06.008_bib91","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A\u00a0phase 1 dose escalation study of the safety and pharmaco-kinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2014.06.008_bib92","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A\u00a0phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib93","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib94","first-page":"4036","article-title":"A\u00a0phase 1b study of 30-minute infusion carfilzomib 20\/45 and 20\/56 mg\/m2 plus 40 mg weekly dexamethasone in patients with relapsed and\/or refractory (R\/R) multiple myeloma","volume":"120","author":"Badros","year":"2012","journal-title":"ASH Annual Meeting Abstract"},{"key":"10.1016\/j.hoc.2014.06.008_bib95","first-page":"P233","article-title":"Clinical profile of once-daily, modified-release oprozomib tablets in patients with hematologic malignancies: results of a phase IB\/2 trial","author":"Kaufman","year":"2013","journal-title":"EHA Annual Meeting Abstracts"},{"issue":"16","key":"10.1016\/j.hoc.2014.06.008_bib96","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.008_bib97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in\u00a0vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib98","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.hoc.2014.06.008_bib99","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib100","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib101","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib102","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myelome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2014.06.008_bib103","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib104","first-page":"1955","article-title":"ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma","volume":"122","author":"Mark","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.008_bib105","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"17","author":"Lonial","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.hoc.2014.06.008_bib106","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.06.008_bib107","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-009-0856-x","article-title":"Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study","volume":"89","author":"Kim","year":"2010","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.008_bib108","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.008_bib109","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.008_bib110","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/leu.2010.58","article-title":"Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed\/refractory multiple myeloma","volume":"24","author":"Palumbo","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.06.008_bib111","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A\u00a0phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2014.06.008_bib112","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib113","first-page":"1969","article-title":"MM-005: a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"122","author":"Richardson","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib114","first-page":"690","article-title":"Phase I\/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma","volume":"122","author":"Shah","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"key":"10.1016\/j.hoc.2014.06.008_bib115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.hoc.2014.06.008_bib116","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"San-Miguel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2014.06.008_bib117","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.hoc.2014.06.008_bib118","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib119","first-page":"1970","article-title":"Time to event analyses in PANORAMA 2: a phase 2 study of panobinostat, bortezomib, and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib120","first-page":"480","article-title":"Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial","volume":"118","author":"Siegel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.008_bib121","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.hoc.2014.06.008_bib122","first-page":"18572","article-title":"Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1)","volume":"30","author":"San-Miguel","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib123","first-page":"759","article-title":"ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM)","volume":"118","author":"Raje","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.008_bib124","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A\u00a0phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2014.06.008_bib125","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib126","first-page":"202","article-title":"A\u00a0phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed\/refractory multiple myeloma (R\/R MM): updated results","volume":"120","author":"Richardson","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"16","key":"10.1016\/j.hoc.2014.06.008_bib127","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.hoc.2014.06.008_bib128","first-page":"8512","article-title":"Phase I\/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma","volume":"31","author":"Lokhorst","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib129","first-page":"277","article-title":"CD38-targeted immunochemotherapy of multiple myeloma: preclinical evidence for its combinatorial use in lenalidomide and bortezomib refractory\/intolerant MM patients","volume":"122","author":"Nijhof","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib130","first-page":"1986","article-title":"Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma","volume":"122","author":"Plesner","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib131","first-page":"284","article-title":"SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies- data from a dose-escalation phase I study","volume":"122","author":"Martin","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib132","first-page":"285","article-title":"Prolonged survival and improved response rates with ARRY-520 in relapsed\/refractory multiple myeloma (RRMM) patients with low \u03b1-1 acid glycoprotein (AAG) levels: results from a phase 2 study","volume":"122","author":"Lonial","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib133","first-page":"1982","article-title":"Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520\u00a0+ carfilzomib (Car) in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"122","author":"Shah","year":"2013","journal-title":"ASH Annual Meeting Abstract"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.008_bib134","first-page":"1938","article-title":"A\u00a0phase 1 study of ARRY-520 with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM)","volume":"122","author":"Chari","year":"2013","journal-title":"ASH Annual Meeting Abstract"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:01:07Z","timestamp":1760184067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858814000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0889858814000823"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2014.06.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapsed and Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2014.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}